Medicaments and proteins based on TGF-β monomers for...

Details Medicaments and proteins based on TGF-β monomers for... Medicaments and proteins based on TGF-β monomers for...

2011-03-08

2011-03-08

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S009400, C514S021200

Reexamination Certificate

active

07902150

ABSTRACT:
There is provided the use of monomeric TGF-βs, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-β3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.

REFERENCES:
patent: 4051848 (1977-10-01), Levine
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5411940 (1995-05-01), Nixon et al.
patent: 5650494 (1997-07-01), Cerletti et al.
patent: 5922846 (1999-07-01), Cerletti et al.
patent: 5958411 (1999-09-01), Logan et al.
patent: 6054122 (2000-04-01), MacPhee et al.
patent: 6057430 (2000-05-01), Cerletti
patent: 6132759 (2000-10-01), Schacht et al.
patent: 6331298 (2001-12-01), Ferguson et al.
patent: 6559123 (2003-05-01), Iwata et al.
patent: 6972321 (2005-12-01), Hotten et al.
patent: 7341994 (2008-03-01), Ishikawa et al.
patent: 7691816 (2010-04-01), Ferguson et al.
patent: 2004/0078851 (2004-04-01), Huang et al.
patent: 0200341 (1986-11-01), None
patent: 0 433 225 (1991-06-01), None
patent: 0 891 985 (1999-01-01), None
patent: 0 943 690 (1999-09-01), None
patent: 1 557 468 (2005-07-01), None
patent: WO90/03812 (1990-04-01), None
patent: WO-91/05565 (1991-05-01), None
patent: WO93/19769 (1993-10-01), None
patent: WO-95/16034 (1995-06-01), None
patent: WO96/03432 (1996-02-01), None
patent: WO96/32131 (1996-10-01), None
patent: WO-97/05166 (1997-02-01), None
patent: WO-99/18196 (1999-04-01), None
patent: WO-00/20607 (2000-04-01), None
patent: WO-00/20612 (2000-04-01), None
patent: WO00/54797 (2000-09-01), None
patent: WO 00/56879 (2000-09-01), None
patent: WO-01/75132 (2001-10-01), None
patent: WO-01/92298 (2001-12-01), None
patent: WO-02/12336 (2002-02-01), None
patent: WO02/076494 (2002-10-01), None
patent: WO-02/099067 (2002-12-01), None
patent: WO-2006/023782 (2006-03-01), None
patent: WO-2006/118617 (2006-11-01), None
patent: WO-2007/007098 (2007-01-01), None
patent: WO-2007/104934 (2007-09-01), None
patent: WO-2007/104945 (2007-09-01), None
patent: WO-2008/032035 (2008-03-01), None
patent: WO-2008/032035 (2008-03-01), None
Ejima et al., “A Novel “Reverse Screening” to Identify Refolding Additives for Activin-A”Science Direct, Protein Expression and Purification, vol. 47 (2006), pp. 45-51.
Patent Cooperation Treaty (PCT) International Search Report, International Application No. PCT/GB2007/003416, completed Dec. 10, 2007, mailed Dec. 18, 2007.
U.S. Appl. No. 12/282,456—Non-Final Office Action dated Oct. 21, 2009, including Form PTO-892 (documents cited therein included by reference).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, vol. 247, No. 4948, pp. 1306-1310 (1990).
Brannon, “Skin Anatomy,” dermatology.about.com/cs/skinanatomy/a/anatomy.htm, downloaded Aug. 16, 2009.
Hao et al., TGF-β3: “A promising growth factor in engineered organogenesis,”Expert Opin. Boll. Ther., vol. 8, No. 10, pp. 1485-1493 (2008).
Hirshberg, TGF—β3 in the Treatment of Pressure Ulcers: A Preliminary Report,Advances in Skin&Wound Care, vol. 14, No. 2, pp. 91-95, www.woundcarenet.com (Mar./Apr. 2001).
International Search Report for WO2007/007098 (PCT/GB2006/002577) dated Mar. 3, 2007 (4 pages).
Martin, “Wound Healing—Aiming for Perfect Skin Regeneration,”Science, vol. 276, pp. 75-81 (1997).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Merz et al, eds, Birkhauser, Boston, pp. 433-506 (1994).
Shah et al., “Neutralisation of TGF-β1and TGF- β2or exogenous addition of TGF-β3to cutaneous rat wounds reduces scarring,”Journal of Cell Science, vol. 108, pp. 985-1002 (1995).
Singer et al., “Cutaneous Wound Healing,”The New England Journal of Medicine, vol. 341, No. 10, pp. 738-746 (1999).
Tyrone et al., “Transforming Growth Factor β3Promotes Fascial Wound Healing in a New Animal Model,”Arch. Surg., vol. 135, pp. 1154-1159, www.archsurg.com, (Oct. 2000).
U.S. Appl. No. 11/995,380: File History of all prosecution documents to date, including Bibliographic Data Page and Image File Wrapper Pages from PAIR as downloaded on Aug. 13, 2010.
U.S. Appl. No. 12/282,456: Final Office Action dated May 26, 2010 (8 pages).
U.S. Appl. No. 12/282,463: File History of all prosecution documents to date, including Bibliographic Data Page and Image File Wrapper Pages from PAIR as downloaded on Aug. 21, 2010.
U.S. Appl. No. 12/440,688: File History of all prosecution documents to date, including Bibliographic Data Page and Image File Wrapper Pages from PAIR as downloaded on Aug. 13, 2010.
Vooijs et al., “Transforming growth factor-β3—loaded microtextured membranes for skini regeneration in dermal wounds,”Journal of biomedical Materials Research, vol. 70, No. 3, pp. 402-411 (2004).
Wang et al., “A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1(EDG1) and LPA1(EDG2) Phospholipid Growth Factor Receptors,”The Journal of Biological Chemistry, vol. 276, No. 52, pp. 49213-49220 (2001).
Wells, “Additivity of Mutational Effects in Proteins,”Biochemistry, vol. 29, No. 37, pp. 8509-8517 (1990).
International Search Report for PCT/GB2007/00814, mailed Nov. 7, 2007.
International Search Report for PCT/GB2007/00833, mailed Mar. 14, 2008.
International Search Report for PCT/GB2007/00834, mailed Apr. 3, 2008.
O'Kane et al. “Transforming Growth Factor βs and Wound Healing” Int. J. Biochem. Cell Biol. vol. 29, No. 1, pp. 63-78 (1997).
Schmid et al. “TGF-βs and TGF-βType II Receptor in Human Epidermis: Differential Expression in Acute and Chronic Skin Wounds” J. of Pathology, vol. 171, pp. 191-197 (993).
Vallejo et al. “Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration,” Biotechnology and Bioengineering, Interscience Publishers, London, GB, vol. 85, No. 6., pp. 601-609, 2004.
Vallejo et al. “Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell density cultures of recombinantEscherichia coli,” J. of Biotech., Elsevier Science Publishes B.V., Amsterdam, NL vol. 94, No. 2., pp. 185-194, 2002.

Affiliated with

Also associated with

Rating

Medicaments and proteins based on TGF-β monomers for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicaments and proteins based on TGF-β monomers for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicaments and proteins based on TGF-β monomers for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2722585